EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

A Novel Oncogenic and Drug-Sensitive KIF5B-NTRK1 Fusion in Lung Adenocarcinoma

Hui Li, Huicong Liu, Lisha Xiao, Huabin Gao, Huiting Wei, Anjia Han iD, Gengpeng Lin

Current Oncology · 24.10.2024 · 31 (11) · 6621-6631

DOI: 10.3390/curroncol31110489 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, online erschienen am 24.10.2024. Verfasst von Hui Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Kinesins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Finance Foundation for Industrial Technology Research and Development (20160907) and Guangdong Basic and Applied Basic Research Foundation (2021A1515…, Guangdong Finance Foundation for Industrial Technology Research and Development, Guangdong Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present a case of a lung adenocarcinoma patient harboring a novel kinesin family member 5B (KIF5B)-NTRK1 gene fusion that responds well to entrectinib. Moreover, KIF5B-NTRK1 gene chimera has been shown to be an oncogene, activating both the MAPK and PI3K/AKT signaling pathways. The biopsy sample was analyzed using various methods such as hematoxylin–eosin staining (HE), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) based on a 1267-gene panel. Additionally, human lung adenocarcinoma cell lines A549 and H1755 were used to obtain a stable expression of chimera gene products. The cell proliferation was confirmed using CCK8 and adhesion-dependent colony formation assay. Cell invasion was confirmed using the transwell invasion assay. The protein levels of the MAPK and PI3K/AKT signaling pathways were assessed using Western blotting. The patient, a 66-year-old Chinese male, was diagnosed with adenocarcinoma (stage IVB) located in the upper lobe of the left lung. NGS analysis identified a novel KIF5B-NTRK1 fusion gene, which was further confirmed by FISH and IHC analyses. As a first-line therapy, entrectinib was administered to the patient at a dose of 600 mg once daily, resulting in a partial response. The patient’s progression-free survival (PFS) has now been more than 12 months, and no serious toxicities have been observed so far. Furthermore, stable KIF5B-NTRK1-expressing cells were generated and the experimental results demonstrate enhanced proliferation abilities, along with increased levels of proteins involved in the MAPK and PI3K/AKT signaling pathways. Our study reports a novel KIF5B-NTRK1 genetic rearrangement that supports favorable responses to entrectinib. Moreover, in vitro experiments showed that the fusion gene could exert oncogenic properties by activating the MAPK and PI3K/AKT signaling pathways. To summarize, our findings broaden the spectrum of NTRK gene fusions in the context of lung adenocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsKinesinsHumansMaleAgedOncogene Proteins, FusionIndazolesBenzamides

Stichwörter der Autor:innen

KIF5B-NTRK1case reportentrectiniblung adenocarcinomasignaling pathways

Substanzen

KinesinsKIF5B protein, humanOncogene Proteins, FusionIndazolesBenzamidesentrectinib

Autor:innen und Institutionen

  • Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
  • Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Institute of Pulmonary Diseases, Sun Yat-sen University, Guangzhou 510080, China.

ORCID-Profile: Anjia Han

Förderung

  • Guangdong Finance Foundation for Industrial Technology Research and Development (20160907) and Guangdong Basic and Applied Basic Research Foundation (2021A1515…
  • Guangdong Finance Foundation for Industrial Technology Research and Development
  • Guangdong Basic and Applied Basic Research Foundation

Zitieren

APA

Li, H., Liu, H., Xiao, L., Gao, H., Wei, H., Han, A., & Lin, G. (2024). A Novel Oncogenic and Drug-Sensitive KIF5B-NTRK1 Fusion in Lung Adenocarcinoma. Current Oncology, 31(11), 6621-6631. https://doi.org/10.3390/curroncol31110489

Vancouver

Li H, Liu H, Xiao L, Gao H, Wei H, Han A, et al. A Novel Oncogenic and Drug-Sensitive KIF5B-NTRK1 Fusion in Lung Adenocarcinoma. Current Oncology. 2024;31(11):6621-6631. doi:10.3390/curroncol31110489

BibTeX
@article{Li2024,
  author = {Li, Hui and Liu, Huicong and Xiao, Lisha and Gao, Huabin and Wei, Huiting and Han, Anjia and Lin, Gengpeng},
  title = {A Novel Oncogenic and Drug-Sensitive KIF5B-NTRK1 Fusion in Lung Adenocarcinoma},
  journal = {Current Oncology},
  year = {2024},
  volume = {31},
  number = {11},
  pages = {6621--6631},
  doi = {10.3390/curroncol31110489}
}
Kostenlos starten →